Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Human Genome Epidemiology Literature Finder|Home|PHGKB

Human Genome Epidemiology Literature Finder


Last data update: Dec 2, 2023. (Total: 223516Documents)
   dataset        GWAS Only
Filtered By:

Previous    

Records 1 - 30 (of 177 Records)

Next

Query Trace: Lung Neoplasms and meta-analysis and EGFR[original query]
Optimal Treatments for NSCLC Patients Harboring Primary or Acquired MET Amplification.
Technology in cancer research & treatment 2022 9 21 15330338221128414.
Sun Dantong, Tao Junyan, Yan Weihua, Zhu Jingjuan, Zhou Hai, Sheng Yingying, Xue Chaofan, Li Hong, Hou Hel
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials.
BMJ open 2022 8 12 (8): e062036.
Deng Wusheng, Wang Ke, Jiang Yun, Li Dingbin, Bao Chongxi, Luo Jing, Liu Liuyuan, Huang Bing, Kong Jinlia
Efficacy and safety of EGFR inhibitors and radiotherapy in locally advanced non-small-cell lung cancer: a meta-analysis.
Future oncology (London, England) 2022 8 18 (27): 3055-3065.
Li Xue, Wang Fang, Jia Huijun, Lian Zhen, Ren Kai, Yuan Zhiyong, Wang Ping, Zhao Luj
Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic Review and Meta-analysis.
Frontiers in oncology 2022 12 863666.
Yi Xiao-Fang, Song Jun, Gao Ruo-Lin, Sun Li, Wu Zhi-Xuan, Zhang Shu-Ling, Huang Le-Tian, Ma Jie-Tao, Han Cheng-
Computed tomography-guided lung biopsy for molecular tests: a meta-analysis.
Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery 2022 Jun 19 (2): 96-101.
Zhang Jian-Hua, Xia Feng-Fei, Yang Xiao-Shan, Li
Prognostic value of soluble programmed cell death ligand-1 in patients with non-small-cell lung cancer: a meta-analysis.
Immunotherapy 2022 7 14 (12): 945-956.
Wang Yan, He Haiy
Impact of Smoking Status in Combination Treatment with EGFR Tyrosine Kinase Inhibitors and Anti-Angiogenic Agents in Advanced Non-Small Cell Lung Cancer Harboring Susceptible EGFR Mutations: Systematic Review and Meta-Analysis.
Journal of clinical medicine 2022 Jun 11 (12): .
Lee Tai-Huang, Chen Hsiao-Ling, Chang Hsiu-Mei, Wu Chiou-Mei, Wu Kuan-Li, Kuo Chia-Yu, Wei Po-Ju, Chen Chin-Ling, Liu Hui-Lin, Hung Jen-Yu, Yang Chih-Jen, Chong Inn-W
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis.
ESMO open 2022 Jun 7 (3): 100507.
Dafni U, Soo R A, Peters S, Tsourti Z, Zygoura P, Vervita K, Han J-Y, De Castro J, Coate L, Früh M, Hashemi S M S, Nadal E, Carcereny E, Sala M A, Bernabé R, Provencio M, Cuffe S, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel R
Adjuvant EGFR tyrosine kinase inhibitors for patients with resected EGFR-mutated non-small-cell lung cancer: a network meta-analysis.
Future oncology (London, England) 2022 6 18 (21): 2695-2707.
Tian Wentao, Tan Nuopei, Ke Jiawen, Zou Ji'an, Liu Xiaohan, Pan Yue, Zeng Yue, Peng Yurong, Wu Fa
Concomitant Gastric Acid Suppressants on the Survival of Patients with Non-Small-Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Meta-Analysis.
International journal of clinical practice 2022 6 2022 3102641.
Xia Jun, Zhu Jiping, Li Lei, Xu Shiq
Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.
BMC cancer 2022 3 22 (1): 328.
Zhao Pengfei, Zhen Hongchao, Zhao Hong, Zhao Lei, Cao Bangw
RT-based combination therapy for brain metastasis from NSCLC with non-EGFR mutation/ALK gene rearrangement: A network meta-analysis.
Frontiers in oncology 2022 12 12 1024833.
Wu Min, Jiang Jun, Zhang Xuewen, Chen Jie, Chang Qiaomei, Chen Ro
A meta-analysis of adjuvant EGFR-TKIs for patients with EGFR mutation of resected non-small cell lung cancer.
Medicine 2022 12 101 (47): e31894.
Cui Ran, Wei Chun, Li Xianyi, Jiang
EGFR Tyrosine Kinase Inhibitor Efficacy in Older Adult Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer: A Meta-Analysis and Systematic Review.
Medicina (Kaunas, Lithuania) 2022 11 58 (11): .
Chen Chang-Hung, Chou Deng-Wei, Chung Kuo-Mou, Chang Han-
Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies.
Acta oncologica (Stockholm, Sweden) 2022 10 61 (11): 1347-1353.
Li Li, Huang Qin, Sun Jianhai, Yan Fei, Wei Wujie, Li Zihui, Liu Li, Deng J
Concurrent TP53 mutations predict a poor prognosis of EGFR-mutant NSCLCs treated with TKIs: An updated systematic review and meta-analysis.
Oncology letters 2022 Nov 24 (5): 384.
Lan Bo, Zhao Na, Du Kang, Leng Baola
First-line therapeutic strategy for patients with advanced non-small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis.
Therapeutic advances in chronic disease 2022 10 13 20406223221125706.
Chen Chongxiang, Zhang Chunning, Lin Huaming, Liu Qianyin, Wu Limian, Zhou Chengzhi, Zhang Jiex
Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta-analysis of real-world survival outcomes of East Asian patients with advanced non-small cell lung cancer treated with first-line EGFR-TKIs.
Thoracic cancer 2023 9 .
Huang-Chih Chang, Chin-Chou Wang, Chia-Cheng Tseng, Kuo-Tung Huang, Yu-Mu Chen, Yu-Ping Chang, Chien-Hao Lai, Wen-Feng Fang, Meng-Chih Lin, Hung-Yi Chua
Survival outcomes of east Asian patients with advanced non-small cell lung cancer treated with first-line EGFR tyrosine kinase inhibitors: A network meta-analysis of real-world evidence.
Thoracic cancer 2023 9 .
Huang-Chih Chang, Kuo-Tung Huang, Chia-Cheng Tseng, Yu-Mu Chen, Chien-Hao Lai, Yu-Ping Chang, Yung-Che Chen, Hung-Yi Chuang, Chin-Chou Wa
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials.
European journal of medical research 2023 8 28 (1): 302.
Ruijian Li, Weiyi Li, Fang Zhang, Shanshan
The efficacy and safety of immune checkpoint inhibitors for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy: A systematic review and network meta-analysis.
Cancer medicine 2023 8 .
Zhen Wang, Fang Zhou, Shan Xu, Kang Wang, Huan Di
Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis.
BMC pulmonary medicine 2023 6 23 (1): 207.
Di Hu, Yan-Yan Zhou, Hong-Bo Ma, Miao-Miao Tao, Qun-Zhen Huang, Zhen-Zhou Yang, Qi Zh
Infection with human cytomegalovirus, Epstein-Barr virus, and high-risk types 16 and 18 of human papillomavirus in EGFR-mutated lung adenocarcinoma.
Croatian medical journal 2023 5 64 (2): 84-92.
Suzana Harabajsa, Hajdi Šef?i?, Marija Klasi?, Marija Milavi?, Snježana Židovec Lepej, Ivana Grgi?, Matea Zajc Petranovi?, Marko Jakopovi?, Silvana Smojver-Ježek, Petra Kor
Should We Perform Repeated Re-Biopsy for the Detection of T790M Mutation?
Cancer research and treatment 2023 4 .
Saerom Kim, Soo Han Kim, Jinmi Kim, Mi-Hyun Kim, Min Ki Lee, Jung Seop E
Epidermal growth factor receptor inhibitors as adjuvant treatment for patients with resected non-small cell lung cancer harboring EGFR mutation: a meta-analysis of randomized controlled clinical trials.
World journal of surgical oncology 2023 2 21 (1): 45.
Zhao Ning, Wu Zhuo-Peng, Yang Jie, Feng Wei-Neng, Yang Sheng-Li, Luo Ying, Ye Jun, Wang Fei, Zhang Xiao-Wen, Xiao Ye, Wu Ling-Ling, Gu Wei-Qu
Safety of Readministration of EGFR-TKI After Onset of Interstitial Lung Disease in Advanced EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis.
Clinical lung cancer 2023 11 .
Fumihiro Kashizaki, Hao Chen, Atsushi Miyasaka, Nanami Tsuchiya, Chihiro Yamada, Shunsuke Okazaki, Mai Kaneko, Taiki Kano, Yohei Kameda, Akitomo Kikuchi, Kentaro Yumoto, Hiroyuki Osawa, Harumi Koizumi, Kenichi Takahashi, Takeshi Kane
Adjuvant therapy in completely resected, EGFR-mutant non-small cell lung cancer: a comparative analysis of treatment efficacy between EGFR-TKI and anti-PD-1/PD-L1 immunotherapy.
Journal for immunotherapy of cancer 2023 10 11 (10): .
Zichun Li, Xuanye Zhang, Yuhong Wang, Zhixin Yu, Chunlong Yang, Yixin Zhou, Shaodong Ho
Efficacy and safety of antiangiogenic agents or chemotherapy plus EGFR-TKIs in advanced non-small cell lung cancer: A systematic review and network meta-analysis.
Thoracic cancer 2023 1 14 (6): 535-543.
Dai Jiali, Liu Xinyin, Li Jun, Qu Tianyu, Cui Yanan, Jin Shidai, Zhang Erbao, Guo Renh
Comparison of gefitinib plus chemotherapy versus gefitinib alone for advanced non?small?cell lung cancer: A meta analysis.
Clinics (Sao Paulo, Brazil) 2023 1 78 100152.
Yi Min, He Ting, Wang Kaijin, Wei Yongga
Side effects of tyrosine kinase inhibitors therapy in patients with non-small cell lung cancer and associations with EGFR polymorphisms: A systematic review and meta-analysis.
Oncology letters 2023 1 25 (2): 62.
Obradovic Jasmina, Todosijevic Jovana, Jurisic Vladim
TOP